What due diligence should investors prioritize before backing a clinical-stage entrant in the Fibrotic Diseases Treatment Market?

Scrutinize endpoint selection above all else. Sponsors relying on histological reversal rather than functional decline face longer, costlier trials and less predictable regulatory reception [14]. Read More

How do generic entrants change procurement strategy for hospital formulary committees?

Generic pirfenidone has cut acquisition cost by 40–60% in several markets, freeing budget headroom. Committees increasingly tier generics as first-line and reserve branded agents for documented intolerance [13]. Read More

Which integration challenges slow adoption of AI-based fibrosis staging tools?

Legacy PACS architectures and inconsistent CT acquisition protocols cause most failures. Sites without standardized slice thickness and reconstruction kernels see algorithm performance degrade sharply [19]. Read More

What regulatory nuance distinguishes accelerated approval pathways in hepatic versus pulmonary fibrosis?

Hepatic programmes can use histological surrogate endpoints under accelerated approval, while pulmonary submissions generally require functional outcomes. That asymmetry shortens liver timelines by roughly two years [1]. Read More

How should procurement teams evaluate supplier risk within the Fibrotic Diseases Treatment Market?

Concentrate on API sourcing geography and single-site manufacturing exposure. Several antifibrotic intermediates originate from a narrow supplier base in India and China, creating correlated disruption risk [24]. Read More

Are emerging fibrosis indications commercially viable at current pricing?

Cutaneous and cardiac fibrosis populations are small but orphan-eligible, supporting premium pricing with reduced trial size. Viability depends on securing designation early rather than on volume [21]. Read More

What competitive dynamic most threatens incumbents in the Fibrotic Diseases Treatment Market over the next five years?

Combination therapy from challengers. A biotech pairing a novel mechanism with a generic backbone can undercut branded monotherapy on both efficacy and cost [14]. Read More

Fibrotic Diseases Treatment Market (2026 - 2035)

ID: MRFR/HC/35100-HCR 100 Pages Satyendra Maurya Last Updated: September 17, 2026

Fibrotic Diseases Treatment Market Research Report By Disease Type (Pulmonary Fibrosis, Liver Fibrosis, Cardiac Fibrosis, Renal Fibrosis), By Treatment Type (Antifibrotic Agents, Immunomodulators, Corticosteroids, Enzyme Replacement Therapy), By Route of Administration (Oral, Injectable, Intravenous), By End User (Hospitals, Specialized Clinics, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Fibrotic Diseases Treatment Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)7.8%

2025 Market SizeUSD 27.4 Billion

2035 Market SizeUSD 58.1 Billion

Key Players

Boehringer Ingelheim

F. Hoffmann-La Roche

Bristol Myers Squibb

Gilead Sciences

Novartis

Pfizer

Trends

Escalating Disease Burden
A Pipeline Finally Reaching Readout
Metabolic Liver Disease as a Volume Engine

Opportunities

Combination Regimens as the Next Standard of Care
Asia-Pacific Access Expansion
Biomarker-Stratified Trial and Care Models

Summary Table of Contents Segmentation Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways |
1. 2.1 By Treatment |
2. 2.2 By Application |
3. 2.3 By Geography
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2024) |
2. 3.2 Base Year Assessment (2025) |
3. 3.3 Forecast Market Size (2026–2035) |
4. 3.4 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Escalating Disease Burden |
2. 4.2 A Pipeline Finally Reaching Readout |
3. 4.3 Metabolic Liver Disease as a Volume Engine |
4. 4.4 Diagnostics Pulling Demand Forward
5 Restraints Impact Analysis |
1. 5.1 Cost and Reimbursement Friction |
2. 5.2 Attrition in Late-Stage Development |
3. 5.3 Tolerability and Real-World Persistence
6 Opportunities |
1. 6.1 Combination Regimens as the Next Standard of Care |
2. 6.2 Asia-Pacific Access Expansion |
3. 6.3 Biomarker-Stratified Trial and Care Models |
4. 6.4 Real-World Data and Registry Monetization |
5. 6.5 Underserved Fibrosis Indications
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Machine Learning in Fibrosis Staging |
2. 8.2 Outcomes-Linked Contracting |
3. 8.3 Precision Medicine Displacing One-Size-Fits-All |
4. 8.4 Regenerative and Reversal Approaches
9 Market Segmentation Analysis |
1. 9.1 By Treatment | |
  1. 9.1.1 Medication | |
  2. 9.1.2 Organ Transplantation | |
  3. 9.1.3 Oxygen Therapy | |
  4. 9.1.4 Others |
2. 9.2 By Application | |
  1. 9.2.1 Idiopathic Pulmonary Fibrosis | |
  2. 9.2.2 Hepatic Cirrhosis | |
  3. 9.2.3 Renal Fibrosis | |
  4. 9.2.4 Cutaneous Fibrosis | |
  5. 9.2.5 Others |
3. 9.3 By End User | |
  1. 9.3.1 Hospitals | |
  2. 9.3.2 Academic and Research Institutes | |
  3. 9.3.3 Others
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Boehringer Ingelheim | |
  2. 10.3.2 F. Hoffmann-La Roche | |
  3. 10.3.3 Bristol Myers Squibb | |
  4. 10.3.4 Gilead Sciences | |
  5. 10.3.5 Novartis | |
  6. 10.3.6 Pfizer | |
  7. 10.3.7 Madrigal Pharmaceuticals | |
  8. 10.3.8 FibroGen | |
  9. 10.3.9 Galapagos NV | |
  10. 10.3.10 Sanofi | |
  11. 10.3.11 Merck KGaA | |
  12. 10.3.12 United Therapeutics
11 Recent News & Developments
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Data Sources & Triangulation |
3. 12.3 Abbreviations
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global Fibrotic Diseases Treatment Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Fibrotic Diseases Treatment Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis Matrix, 2026–2035 |
TABLE 4 Restraint Impact Analysis Matrix, 2026–2035 |
TABLE 5 Global Market Size, by Treatment, 2021–2035 (USD Billion) |
TABLE 6 Global Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 7 Global Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 8 Global Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 9 North America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Europe Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Asia-Pacific Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 South America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 Middle East & Africa Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 North America Market Size, by Treatment, 2021–2035 (USD Billion) |
TABLE 15 North America Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 16 North America Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 17 Europe Market Size, by Treatment, 2021–2035 (USD Billion) |
TABLE 18 Europe Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 19 Europe Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 20 Asia-Pacific Market Size, by Treatment, 2021–2035 (USD Billion) |
TABLE 21 Asia-Pacific Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 22 Asia-Pacific Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 23 South America Market Size, by Treatment, 2021–2035 (USD Billion) |
TABLE 24 South America Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 25 South America Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 26 Middle East & Africa Market Size, by Treatment, 2021–2035 (USD Billion) |
TABLE 27 Middle East & Africa Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 28 Middle East & Africa Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 29 US Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 30 Germany Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 31 China Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 32 Japan Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 33 Brazil Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 34 Saudi Arabia Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 35 Competitive Benchmarking Matrix, 2026 |
TABLE 36 Company Profiles – Key Players |
TABLE 37 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 38 Report Scope & Methodology Summary |
TABLE 39 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Global Market Dynamics – Drivers, Restraints & Opportunities Snapshot |
FIGURE 2 Industry Value Chain Analysis – Discovery to Patient Delivery |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Trajectory, 2022–2035 (%) |
FIGURE 6 Market Share by Treatment, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Application, 2025 vs 2035 (%) |
FIGURE 8 Market Share by End User, 2025 vs 2035 (%) |
FIGURE 9 Regional Market Share Distribution, 2025 (%) |
FIGURE 10 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 11 North America Country-Level Share, 2025 (%) |
FIGURE 12 Europe Country-Level Share, 2025 (%) |
FIGURE 13 Asia-Pacific Country-Level Share, 2025 (%) |
FIGURE 14 Competitive Landscape – Estimated Revenue Share Bands, 2026 |
FIGURE 15 Clinical Pipeline Distribution by Phase and Indication |
FIGURE 16 Strategic Positioning Matrix – Scale vs Pipeline Depth

Get Free Sample PDF

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Treatment	Medication; Organ Transplantation; Oxygen Therapy; Others	Medication	Medication
By Application	Idiopathic Pulmonary Fibrosis; Hepatic Cirrhosis; Renal Fibrosis; Cutaneous Fibrosis; Others	Idiopathic Pulmonary Fibrosis	Renal Fibrosis
By End User	Hospitals; Academic and Research Institutes; Others	Hospitals	Others
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Treatment

Sub-Segment	Key Trend
Medication	Mechanism-targeted oral agents displacing broad immunosuppression; combination regimens entering Phase II
Organ Transplantation	Machine perfusion and expanded donor criteria lifting usable organ yield despite persistent scarcity
Oxygen Therapy	Portable concentrators shifting supportive care from institutional to home settings
Others	Pulmonary rehabilitation and palliative protocols formalized into guideline pathways

Treatment economics tilt decisively toward pharmacology. Drug-based intervention captures the majority of spend and nearly all of the incremental growth, while transplantation grows on procedural cost rather than case volume and supportive modalities compete increasingly on convenience.

By Application

Sub-Segment	Key Trend
Idiopathic Pulmonary Fibrosis	Two established standards of care; first new mechanism in a decade approaching approval
Hepatic Cirrhosis	Metabolic disease screening cascades creating a large newly treatable population
Renal Fibrosis	Fastest-growing indication with minimal approved targeted therapy and high pipeline sensitivity
Cutaneous Fibrosis	Systemic sclerosis and keloid management benefiting from orphan designation pathways
Others	Cardiac and retroperitoneal fibrosis emerging as early-stage research priorities

Application mix is rebalancing away from a single dominant indication. Pulmonary disease still leads on revenue, but hepatic screening infrastructure and renal pipeline activity are steadily widening the commercial base beyond respiratory medicine.

By End User

Sub-Segment	Key Trend
Hospitals	Multidisciplinary review boards and specialist initiation protocols concentrating early treatment decisions
Academic and Research Institutes	Dual role as tertiary referral centres and sponsor-funded trial sites
Others	Specialty clinics and home-based monitoring expanding on remote spirometry and telehealth adoption

Care settings are decentralizing slowly. Hospitals retain control of diagnosis and initiation because staging requires specialist infrastructure, yet maintenance therapy is migrating outward as oral regimens mature and remote monitoring proves reliable.

Get Free Sample PDF

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”